Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares
Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of Editas Medicine stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $29.58, for a total value of $246,490.14. Following the transaction, the insider now directly owns 1,387,897 shares in the company, valued at $41,053,993.26. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Katrine Bosley also recently made the following trade(s):
- On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $23.64, for a total value of $196,992.12.
- On Monday, October 2nd, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $24.78, for a total value of $206,491.74.
Editas Medicine Inc (EDIT) opened at $27.76 on Tuesday. The company has a current ratio of 10.12, a quick ratio of 10.12 and a debt-to-equity ratio of 0.19. Editas Medicine Inc has a 52 week low of $13.12 and a 52 week high of $31.81.
Hedge funds have recently bought and sold shares of the stock. IHT Wealth Management LLC acquired a new position in Editas Medicine during the 2nd quarter worth approximately $107,000. Great West Life Assurance Co. Can raised its stake in Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after buying an additional 4,159 shares during the period. Bank of America Corp DE raised its stake in Editas Medicine by 72.2% during the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Editas Medicine during the 2nd quarter worth approximately $127,000. Finally, Legal & General Group Plc raised its stake in Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares during the period. 70.11% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently issued reports on the company. Cann reissued a “hold” rating on shares of Editas Medicine in a research note on Thursday, August 10th. J P Morgan Chase & Co set a $27.00 price objective on Editas Medicine and gave the company a “hold” rating in a research note on Wednesday, August 9th. Morgan Stanley reissued an “equal weight” rating and issued a $28.00 price objective (up from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. ValuEngine raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Finally, Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $26.73.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/editas-medicine-inc-edit-insider-katrine-bosley-sells-8333-shares.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.